Table 2.

Pharmaceuticals under clinical trials within 2015–2025 for endometriosis (EM) treatment^a

NCT number	Study completion	Phase	Study locations or centers	Medication	Control	Study aim	Outcome measuresb
NCT01769781	Jul‐15	Phase 4	Italy	Anastrazole plus GnRH‐agonist	GnRH analog	Efficacy of drug for EM recurrence	Pelvic pain
NCT01767090	Jul‐15	Phase 2	Belgium, Japan, United Kingdom, and so forth	ASP1707	Placebo and Leuprorelin acetate	Safety and efficacy of drug in different doses for EM‐associated symptoms	Pelvic pain, dysmenorrhea, dyspareunia, adverse events, bleeding pattern
NCT01779232	Sep‐15	Phase 4	Italy	Danazol	Placebo	Efficacy of drug for EM‐related infertility	Fertilization outcome
NCT01822080	Nov‐15	Phase 3	China	Dienogest	Placebo	Efficacy of drug for EM‐related symptoms in Chinese Patients	Pelvic pain, dysmenorrhea, adverse events, bleeding pattern
NCT02475564	Nov‐15	Phase 4	Brazil	Resveratrol	Placebo	Efficacy of drug for EM‐related pain	Pelvic pain, CA125, and prolactin marker
NCT01712763	Mar‐16	Phase 3	Italy	Degarelix	Goserelin	Efficacy of drug for EM recurrence	Pelvic pain
NCT01760954	Apr‐16	Phase 3	AbbVie Inc.	Elagolix	N/A	Long‐term safety and efficacy of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, quality of life, adverse Events
NCT02534688	May‐16	Phase 4	Thailand	LNG‐IUS and DMPA	N/A	Efficacy of drug for EM‐related symptoms	Pelvic pain, quality of life, hormone profile
NCT02387931	Jul‐16	Phase 4	United States	Vitamin D3 and Fish Oil	Placebo	Efficacy of drug for adolescent girls with EM‐related symptoms	Pelvic pain, quality of life
NCT02427386	Dec‐16	Phase 4	University of Sao Paulo General Hospital	Dynamized estrogen	Placebo	Efficacy of drug for EM‐related symptoms	Pelvic pain
NCT01931670	Dec‐16	Phase 3	AbbVie Inc.	Elagolix	Placebo	Safety and efficacy of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, quality of life
NCT01728454	Mar‐17	Phase 2	United States	Telapristone acetate	Placebo	Safety and efficacy of drug for EM‐related symptoms in premenopausal women	Pelvic pain, dysmenorrhea, dyspareunia
NCT02143713	May‐17	Phase 3	AbbVie Inc.	Elagolix	Placebo	Long‐term safety and efficacy of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, quality of life, adverse Events
NCT02480647	Aug‐17	Phase 4	Brazil	Levonorgestrel and Etonogestrel	N/A	Efficacy of drug for EM‐related symptoms	Pelvic pain, bleeding pattern
NCT02542410	Sep‐18	Phase 2	United States	Cabergoline	Norethindrone acetate	Efficacy of drug for EM‐related symptoms	Pelvic pain
NCT02778399	Jul‐19	Phase 2	United States, Poland, Russian Federation, Ukraine, and so forth	OBE2109	Placebo	Efficacy and safety for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, dyschezia, quality of life, adverse events
NCT01553201	Jul‐19	Phase 1|Phase 2	United States	Botulinum Toxin	Placebo	Efficacy of drug for EM‐related symptoms	Pelvic pain
NCT03232281	Nov‐19	Phase 3	China	Triptorelin Pamoate PR 3‐month and Triptorelin Acetate PR 1‐month	N/A	Efficacy and safety of drug for EM‐related symptoms in Chinese patients	Pelvic pain, percentage of subjects castrated, hormones profile
NCT03340324	Dec‐19	Phase 2	Mongolia	V‐Endo	N/A	Efficacy of drug for EM‐related symptoms	Pelvic pain, complete blood count, liver and kidney function
NCT03352076	May‐20	Phase 2	Italy	Vaginal danazol and oral danatrol	N/A	Concentration of drug for EM‐related symptoms	Danazol concentration
NCT03654326	Jun‐20	Phase 2	United States, Australia, Chile, New Zealand, and so forth	Gefapixant	Naproxen and Placebo	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, adverse events
NCT03931915	Sep‐20	Phase 3	Japan	TAK‐385 and leuprorelin acetate	N/A	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, dyspareunia, adverse events, serum concentrations, menstrual pain
NCT03573336	Oct‐20	Phase 2	United States, Austria, Canada, Japan, and so forth	Vilaprisan	Placebo	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, adverse events, clinical imaging assessments
NCT02832271	Dec‐20	Phase 2	Hong Kong	SUNPHENON EGCG	Placebo	Efficacy and safety of drug for EM‐related symptoms and lesion size	Pelvic pain, lesion size, quality of life, adverse events
NCT03782740	Feb‐21	Phase 2	Sweden	Melatonin	Placebo	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, quality of life, adverse events, acceptance of melatonin
NCT03204331	Mar‐21	Phase 3	United States, Australia, Brazil, Chile, and so forth	Relugolix	Estradiol/norethindrone acetate, Placebo	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, quality of life, adverse events, hormone profiles
NCT03204318
NCT03749109	May‐21	Phase 2	Denmark, Germany, Italy, Poland, and so forth	Quinagolide	Placebo	Efficacy and safety of drug for EM‐related symptoms and lesion size	Lesion size, dysmenorrhea, quality of life, adverse events, clinical imaging assessments
NCT01942122	Jun‐21	Phase 2|Phase 3	Indonesia	DLBS1442	Mefenamic acid	Efficacy of drug for EM‐related symptoms	Pelvic pain, quality of life, adverse events, inflammatory markers, hormone profile
NCT03840993	Aug‐21	Phase 2	United States	MT‐2990	Placebo	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain
NCT04256200	Dec‐21	Phase 2|Phase 3	Lebanon	Dienogest 2‐mg oral tablet	Oral Contraceptive Pills	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, quality of life, adverse events, patient tolerability
NCT03991520	Jan‐22	Early Phase 1	United States	Anakinra 100‐mg/0.67‐ml Inj Syringe	Placebo	Efficacy for EM‐related symptoms (pilot study)	Pelvic pain, dysmenorrhea, dyspareunia, quality of life, serum inflammatory markers
NCT03992846	Jul‐22	Phase 3	United States, Austria, Bulgaria, Czechia, and so forth	Linzagolix	Placebo	Efficacy of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, dyschezia
NCT03986944
NCT03654274	Dec‐22	Phase 3	United States, Argentina, Australia, Belgium, and so forth	Relugolix	Estradiol/norethindrone acetate	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, adverse events, hormone profile
NCT03213457	Jan‐23	Phase 3	United States, Canada, Puerto Rico	Elagolix, estradiol/norethindrone acetate	Placebo	Efficacy and safety of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia
NCT03928288	Feb‐23	Phase 2	United States	Cabergoline	Placebo	Efficacy of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, serum angiogenesis and inflammatory biomarkers, adverse events
NCT03970330	May‐23	Phase 3	United States	Naltrexone and norethindrone acetate	Placebo	Efficacy of drug for EM‐related symptoms	Pelvic pain
NCT03692403	Aug‐23	Phase 2	United States	Quinagolide	Placebo	Efficacy of drug for EM‐related symptoms	Pelvic pain, dysmenorrhea, dyspareunia, quality of life, bleeding pattern, adverse events

^aAll information was taken from the US National Library of Medicine, ClinicalTrials.gov, only completed or active clinical trials, and EM treatment as the primary study purpose between 2015 and 2025 are included.

^bSelected outcome measures are shown.